These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31363366)

  • 1. Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis.
    Yang X; Wan M; Yu F; Wang Z
    Exp Ther Med; 2019 Aug; 18(2):1141-1148. PubMed ID: 31363366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis.
    Li Y; Qiu X; Lei Y; Zhou R
    Ann Med; 2024 Dec; 56(1):2329140. PubMed ID: 38470973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
    Choi HY; Yong CS; Yoo BK
    Ann Pharmacother; 2010 Jan; 44(1):117-26. PubMed ID: 20009003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials.
    Luo C; Wu G; Huang X; Zhang Y; Ma Y; Huang Y; Huang Z; Li H; Hou Y; Chen J; Li X; Xu S
    Stem Cell Res Ther; 2022 Mar; 13(1):123. PubMed ID: 35317856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
    Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review.
    Mesquita Augusto Passos R; Feldens TK; Marcolino MAZ; Gouvêa AS; Dos Santos Oliveira L; Menardi Nasser L; Rodrigues RF; de Lourdes Martins Perobelli L; Campolina AG; de Almeida Neto C
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):15-28. PubMed ID: 36285481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.
    Kouroukis CT; Varela NP; Bredeson C; Kuruvilla J; Xenocostas A
    Curr Oncol; 2016 Aug; 23(4):e409-30. PubMed ID: 27536190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges.
    Puzo CJ; Li P; Tormey CA; Siddon AJ
    Lab Med; 2024 Sep; ():. PubMed ID: 39303673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.
    García-Escobar I; Parrilla L; Ortega LM; Castellanos D; Pallarés MA; Cortés-Funés H
    Mol Clin Oncol; 2014 Nov; 2(6):923-926. PubMed ID: 25279175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Hematopoietic Progenitor Cell Mobilization Regimen Comprising Bortezomib, G-CSF, and Preemptive Plerixafor for Multiple Myeloma.
    Tanimoto K; Sakamoto K; Kawano I; Yamanaka I; Henzan H
    Blood Cell Ther; 2020 Nov; 3(4):78-83. PubMed ID: 36711007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.
    Pelus LM; Farag SS
    Stem Cells Cloning; 2011; 4():11-22. PubMed ID: 24198526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.
    Salvino MA; Ruiz J
    Rev Bras Hematol Hemoter; 2016; 38(1):28-36. PubMed ID: 26969772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study.
    Kriegsmann K; Bittrich M; Sauer S; Tietze-Stolley C; Movassaghi K; Grube M; Vucinic V; Wehler D; Burchert A; Schmidt-Hieber M; Rank A; Dürk HA; Metzner B; Kimmich C; Hentrich M; Kunz C; Hartmann F; Khandanpour C; de Wit M; Holtick U; Kiehl M; Stoltefuß A; Kiani A; Naumann R; Scholz CW; Tischler HJ; Görner M; Brand F; Ehmer M; Kröger N
    Transfus Med Hemother; 2023 Oct; 50(5):403-416. PubMed ID: 37899991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.
    Humpe A; Buwitt-Beckmann U; Schub N; Gramatzki M; Günther A
    Transfus Med Hemother; 2013 Aug; 40(4):251-7. PubMed ID: 24179473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update.
    Bilgin YM
    J Blood Med; 2021; 12():403-412. PubMed ID: 34104027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plerixafor for autologous CD34 cell mobilization.
    Salman H; Lazarus HM
    Core Evid; 2011; 6():23-9. PubMed ID: 21468240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India.
    Das S; Kayal S; Dubashi B; Basavarajegowda A; Pasupala NK; Kulkarni R; Dhanraju K; Pani CK
    Asian J Transfus Sci; 2022; 16(1):7-14. PubMed ID: 36199417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.
    Jantunen E; Partanen A; Turunen A; Varmavuo V; Silvennoinen R
    Transfus Med Hemother; 2023 Oct; 50(5):438-447. PubMed ID: 37899993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.